Glycomine is a small clinical-stage biotechnology company dedicated to developing therapeutics for congenital disorders of glycosylation (CDG), which are serious rare diseases that currently lack disease-modifying treatment options. The company focuses on addressing the unmet medical needs of patients and families affected by these conditions, leveraging a multidisciplinary team with diverse expertise. Glycomine's lead clinical program targets PMM2-CDG, aiming to provide innovative solutions that can significantly enhance the quality of life for those impacted by rare diseases.